{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:23:46Z","timestamp":1790504626424,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T00:00:00Z","timestamp":1498780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1038\/leu.2017.207","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T06:41:14Z","timestamp":1498804874000},"page":"343-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":159,"title":["BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells"],"prefix":"10.1038","volume":"32","author":[{"given":"B","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Fiskus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Rajapakshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Raina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K G","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A P","family":"Crew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D T","family":"Saenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C P","family":"Mill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J D","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Coarfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"Crews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K N","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,30]]},"reference":[{"key":"BFleu2017207_CR1","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","volume":"123","author":"J Zhang","year":"2014","unstructured":"Zhang J, Jima D, Moffitt AB, Liu Q, Czader M, Hsi ED et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood 2014; 123: 2988\u20132996.","journal-title":"Blood"},{"key":"BFleu2017207_CR2","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares P, Colomer D, Campo E . Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012; 122: 3416\u20133423.","journal-title":"J Clin Invest"},{"key":"BFleu2017207_CR3","doi-asserted-by":"publisher","first-page":"18250","DOI":"10.1073\/pnas.1314608110","volume":"110","author":"S Be\u00e0","year":"2013","unstructured":"Be\u00e0 S, Vald\u00e9s-Mas R, Navarro A, Salaverria I, Mart\u00edn-Garcia D, Jares P et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA 2013; 110: 18250\u201318255.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017207_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.semcancer.2011.09.008","volume":"21","author":"S Parekh","year":"2011","unstructured":"Parekh S, Weniger MA, Wiestner A . New molecular targets in mantle cell lymphoma. Semin Cancer Biol 2011; 21: 335\u2013346.","journal-title":"Semin Cancer Biol"},{"key":"BFleu2017207_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nrd3937","volume":"12","author":"RM Young","year":"2013","unstructured":"Young RM, Staudt LM . Targeting pathological B cell receptor signaling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229\u2013243.","journal-title":"Nat Rev Drug Discov"},{"key":"BFleu2017207_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","volume":"117","author":"P Perez-Galan","year":"2011","unstructured":"Perez-Galan P, Dreyling M, Wiestner A . Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117: 26\u201338.","journal-title":"Blood"},{"key":"BFleu2017207_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","volume":"125","author":"E Campo","year":"2015","unstructured":"Campo E, Rule S . Mantle cell lymphoma: evolving management strategies. Blood 2015; 125: 48\u201355.","journal-title":"Blood"},{"key":"BFleu2017207_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507\u2013516.","journal-title":"N Engl J Med"},{"key":"BFleu2017207_CR9","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-14-0010","volume":"20","author":"A Herrera","year":"2014","unstructured":"Herrera A, Jacobsen ED . Ibrutinib for the treatment of mantle cell lymphoma. Clin Cancer Res 2014; 20: 5365\u20135371.","journal-title":"Clin Cancer Res"},{"key":"BFleu2017207_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015; 126: 739\u2013745.","journal-title":"Blood"},{"key":"BFleu2017207_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nm.3435","volume":"20","author":"R Rahal","year":"2014","unstructured":"Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC et al. Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma. Nat Med 2014; 20: 87\u201392.","journal-title":"Nat Med"},{"key":"BFleu2017207_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccr.2013.12.011","volume":"25","author":"D Colomer","year":"2014","unstructured":"Colomer D, Campo E . Unlocking new therapeutic targets and resistance mechanisms in mantle cell lymphoma. Cancer Cell 2014; 25: 7\u20139.","journal-title":"Cancer Cell"},{"key":"BFleu2017207_CR13","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1182\/blood-2016-04-711176","volume":"128","author":"C Jacobson","year":"2016","unstructured":"Jacobson C, Kopp N, Layer JV . HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood 2016; 128: 2517\u20132526.","journal-title":"Blood"},{"key":"BFleu2017207_CR14","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood-2015-04-639542","volume":"126","author":"B Sun","year":"2015","unstructured":"Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C et al. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood 2015; 126: 1565\u20131574.","journal-title":"Blood"},{"key":"BFleu2017207_CR15","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S et al. DRUG DEVELOPMENT. Phthalidimide conjugation as a strategy for in vivo target protein degradation. Science 2015; 348: 1376\u20131381.","journal-title":"Science"},{"key":"BFleu2017207_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1146\/annurev.immunol.021908.132641","volume":"27","author":"S Vallabhapurapu","year":"2009","unstructured":"Vallabhapurapu S, Karin M . Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693\u2013733.","journal-title":"Annu Rev Immunol"},{"key":"BFleu2017207_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","volume":"132","author":"MS Hayden","year":"2008","unstructured":"Hayden MS, Ghosh S . Shared principles in NF-kappaB signaling. Cell 2008; 132: 344\u2013362.","journal-title":"Cell"},{"key":"BFleu2017207_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang CV . MYC on the path to cancer. Cell 2012; 149: 22\u201335.","journal-title":"Cell"},{"key":"BFleu2017207_CR19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","volume":"22","author":"J Lu","year":"2015","unstructured":"Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol 2015; 22: 755\u2013763.","journal-title":"Chem Biol"},{"key":"BFleu2017207_CR20","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/anie.201507978","volume":"55","author":"M Toure","year":"2016","unstructured":"Toure M, Crews CM . Small-molecule PROTACS: new approaches to protein degradation. Agnew Chem Int Ed Engl 2016; 55: 1966\u20131973.","journal-title":"Agnew Chem Int Ed Engl"},{"key":"BFleu2017207_CR21","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.1521738113","volume":"113","author":"K Raina","year":"2016","unstructured":"Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AM et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci USA 2016; 113: 7124\u20137129.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017207_CR22","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","volume":"21","author":"M Boi","year":"2015","unstructured":"Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C et al. The inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res 2015; 21: 1628\u20131638.","journal-title":"Clin Cancer Res"},{"key":"BFleu2017207_CR23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nm.4128","volume":"22","author":"R Eichner","year":"2016","unstructured":"Eichner R, Heider M, Fern\u00e1ndez-S\u00e1iz V, van Bebber F, Garz AK, Lemeer S et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med 2016; 22: 735\u2013743.","journal-title":"Nat Med"},{"key":"BFleu2017207_CR24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nmeth.1226","volume":"5","author":"A Mortazavi","year":"2008","unstructured":"Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B . Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008; 5: 621\u2013628.","journal-title":"Nat Methods"},{"key":"BFleu2017207_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27\u201355.","journal-title":"Adv Enzyme Regul"},{"issue":"9","key":"BFleu2017207_CR26","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/leu.2016.393","volume":"31","author":"D T Saenz","year":"2017","unstructured":"Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K et al. Novel BET protein proteolysis targeting chimera (BET-PROTAC) exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Leukemia 2017. e-pub ahead of print 31 January 2017, doi:10.1038\/leu.2016.393.","journal-title":"Leukemia"},{"key":"BFleu2017207_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69\u201380.","journal-title":"Cell"},{"key":"BFleu2017207_CR28","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/leu.2015.142","volume":"30","author":"SG Devaraj","year":"2016","unstructured":"Devaraj SG, Fiskus W, Shah B, Qi J, Sun B, Iyer SP et al. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia 2016; 30: 504\u2013508.","journal-title":"Leukemia"},{"key":"BFleu2017207_CR29","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/leu.2016.260","volume":"31","author":"DT Saenz","year":"2017","unstructured":"Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B et al. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia 2017; 31: 678\u2013687.","journal-title":"Leukemia"},{"key":"BFleu2017207_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1182\/blood-2007-10-119438","volume":"113","author":"SM Kornblau","year":"2009","unstructured":"Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M et al. Functional proteomic profiling of AML predicts response and survival. Blood 2009; 113: 154\u2013164.","journal-title":"Blood"},{"key":"BFleu2017207_CR31","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/onc.2013.179","volume":"33","author":"Z Zou","year":"2014","unstructured":"Zou Z, Huang B, Wu X, Zhang H, Qi J, Bradner J et al. Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA. Oncogene 2014; 33: 2395\u20132404.","journal-title":"Oncogene"},{"key":"BFleu2017207_CR32","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1128\/MCB.01365-08","volume":"29","author":"B Huang","year":"2009","unstructured":"Huang B, Yang XD, Zhou MM, Ozato K, Chen LF . Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol 2009; 29: 1375\u20131387.","journal-title":"Mol Cell Biol"},{"key":"BFleu2017207_CR33","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.molcel.2015.04.011","volume":"58","author":"JS Roe","year":"2015","unstructured":"Roe JS, Mercan F, Rivera K, Pappin DJ, Vakoc CR . BET Bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Mol Cell 2015; 58: 1028\u20131039.","journal-title":"Mol Cell"},{"key":"BFleu2017207_CR34","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/nsmb.2912","volume":"21","author":"T Kanno","year":"2014","unstructured":"Kanno T, Kanno Y, LeRoy G, Campos E, Sun HW, Brooks SR et al. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat Struct Mol Biol 2014; 21: 1047\u20131057.","journal-title":"Nat Struct Mol Biol"},{"key":"BFleu2017207_CR35","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","volume":"155","author":"D Hnisz","year":"2013","unstructured":"Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andr\u00e9 V, Sigova AA et al. Super enhancers in the control of cell identity and disease. Cell 2013; 155: 934\u2013947.","journal-title":"Cell"},{"key":"BFleu2017207_CR36","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","volume":"54","author":"J Shi","year":"2014","unstructured":"Shi J, Vakoc CR . The mechanism behind the therapeutic activity of BET bromodomain inhibition. Mol Cell 2014; 54: 728\u2013736.","journal-title":"Mol Cell"},{"key":"BFleu2017207_CR37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Lov\u00e9n","year":"2013","unstructured":"Lov\u00e9n J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013; 153: 320\u2013334.","journal-title":"Cell"},{"key":"BFleu2017207_CR38","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.molcel.2015.10.033","volume":"60","author":"C Shen","year":"2015","unstructured":"Shen C, Ipsaro JJ, Shi J, Milazzo JP, Wang E, Roe JS et al. NSD3-short is an adaptor protein that couples BRD4 to the CHD8 chromatin remodeler. Mol Cell 2015; 60: 847\u2013859.","journal-title":"Mol Cell"},{"key":"BFleu2017207_CR39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.celrep.2016.03.054","volume":"15","author":"AS Bhagwat","year":"2016","unstructured":"Bhagwat AS, Roe JS, Mok BY, Hohmann AF, Shi J, Vakoc CR . BET bromodomain inhibition releases the mediator complex from select cis-regulatory elements. Cell Rep 2016; 15: 519\u2013530.","journal-title":"Cell Rep"},{"key":"BFleu2017207_CR40","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1093\/nar\/gku449","volume":"42","author":"F Itzen","year":"2014","unstructured":"Itzen F, Greifenberg AK, Bosken CA, Geyer M . Brd4 activates P-TEFB for RNA polymerase II CTD phosphorylation. Nucleic Acids Res 2014; 42: 7577\u20137590.","journal-title":"Nucleic Acids Res"},{"key":"BFleu2017207_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bbagrm.2010.11.001","volume":"1809","author":"S Nechaev","year":"2011","unstructured":"Nechaev S, Adelman K . Pol II waiting in the starting gates: Regulating the transition from transcription initiation into productive elongation. Biochim Biophys Acta 2011; 1809: 34\u201345.","journal-title":"Biochim Biophys Acta"},{"key":"BFleu2017207_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cell.2014.02.009","volume":"157","author":"M Levine","year":"2014","unstructured":"Levine M, Cattoglio C, Tjian R . Looping back to leap forward: transcription enters a new era. Cell 2014; 157: 13\u201325.","journal-title":"Cell"},{"key":"BFleu2017207_CR43","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.cell.2013.02.014","volume":"152","author":"TI Lee","year":"2013","unstructured":"Lee TI, Young RA . Transcriptional regulation and its misregulation in disease. Cell 2013; 152: 1237\u20131251.","journal-title":"Cell"},{"key":"BFleu2017207_CR44","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/bjh.12974","volume":"166","author":"J Ma","year":"2014","unstructured":"Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P et al. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. Br J Haematol 2014; 166: 849\u2013861.","journal-title":"Br J Haematol"},{"key":"BFleu2017207_CR45","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","volume":"4","author":"D Chiron","year":"2014","unstructured":"Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov 2014; 4: 1022\u20131035.","journal-title":"Cancer Discov"},{"key":"BFleu2017207_CR46","doi-asserted-by":"publisher","first-page":"6223","DOI":"10.1038\/onc.2016.155","volume":"35","author":"Y Li","year":"2016","unstructured":"Li Y, Bouchlaka MN, Wolff J, Grindle KM, Lu L, Qian S et al. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. Oncogene 2016; 35: 6223\u20136234.","journal-title":"Oncogene"},{"key":"BFleu2017207_CR47","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","volume":"128","author":"D Chiron","year":"2016","unstructured":"Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood 2016; 128: 2808\u20132818.","journal-title":"Blood"},{"key":"BFleu2017207_CR48","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","volume":"128","author":"NS Saba","year":"2016","unstructured":"Saba NS, Liu D, Herman SE, Underbayev C, Tian X, Behrend D et al. Pathogenic role of B-cell receptor signaling and canonical NF-\u03baB activation in mantle cell lymphoma. Blood 2016; 128: 82\u201392.","journal-title":"Blood"},{"key":"BFleu2017207_CR49","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202\u2013208.","journal-title":"Nat Med"},{"key":"BFleu2017207_CR50","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","volume":"119","author":"JP Leonard","year":"2012","unstructured":"Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ et al. Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119: 4597\u20134607.","journal-title":"Blood"},{"key":"BFleu2017207_CR51","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature14898","volume":"525","author":"P Rathert","year":"2015","unstructured":"Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 2015; 525: 543\u2013547.","journal-title":"Nature"},{"key":"BFleu2017207_CR52","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature14888","volume":"525","author":"CY Fong","year":"2015","unstructured":"Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 2015; 525: 538\u2013542.","journal-title":"Nature"},{"key":"BFleu2017207_CR53","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16508","volume":"529","author":"S Shu","year":"2016","unstructured":"Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 2016; 529: 413\u2013417.","journal-title":"Nature"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017207.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017207","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017207.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:08:22Z","timestamp":1684433302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,30]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["BFleu2017207"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.207","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,30]]},"assertion":[{"value":"15 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CMC is the founder and Chief Scientific Advisor of, and possesses an equity ownership stake in, Arvinas, Inc. YQ, KR, KGC, APC and AS are Arvinas employees and possess an equity ownership stake in Arvinas. The other authors state declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}